CytoDyn Inc. Announces First HIV Patient Dosing With PRO 140 in Phase 2b Clinical Trial for Treatment Substitution Protocol May 14, 2014 8:00am EDT
CytoDyn Announces Investor Call to Provide Update on Clinical Development Strategy Mar 19, 2014 8:05am EDT
CytoDyn Submits Protocol to FDA for Phase 2b Clinical Study of PRO 140 for Treatment Substitution in Patients with HIV Feb 18, 2014 8:05am EST
CytoDyn to Present at 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014 at 10:00 AM Eastern Feb 05, 2014 7:35am EST
CytoDyn Signs Agreement with Amarex Clinical Research LLC to Prepare Two Phase 2b Clinical Trial Protocols to Explore Two Additional Therapeutic Indications for PRO 140 Jan 28, 2014 8:05am EST
CytoDyn to Webcast Presentation at Biotech Showcase 2014 in San Francisco on Monday, January 13, at 2:30 PM Pacific Jan 08, 2014 8:05am EST
